Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Itraconazole
Drug ID BADD_D01217
Description One of the triazole antifungal agents that inhibits cytochrome P-450-dependent enzymes resulting in impairment of ergosterol synthesis. It has been used against histoplasmosis, blastomycosis, cryptococcal meningitis & aspergillosis.
Indications and Usage For the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.
Marketing Status Prescription; Discontinued
ATC Code J02AC02
DrugBank ID DB01167
KEGG ID D00350
MeSH ID D017964
PubChem ID 55283
TTD Drug ID D0V4IB
NDC Product Code 12578-299; 50268-450; 53069-0450; 58032-0110; 0378-5100; 68382-697; 66577-044; 63629-8168; 60687-299; 10147-0150; 70518-3264; 50458-290; 62991-3078; 10147-1700; 71747-002; 65162-630; 67835-5043; 16729-271; 10695-064; 22568-1108; 67877-454; 31722-006; 65162-087; 46708-204; 38779-2759; 62332-204; 60592-318; 72761-019; 70771-1208; 49884-239; 70518-2872; 66039-815; 17511-114; 50458-295; 59349-0012; 13668-463; 0395-8113; 71052-301; 50546-462; 16714-743; 51552-0920; 65015-624; 51862-462
Synonyms Itraconazole | R-51211 | R 51211 | R51211 | Sporanox | Orungal
Chemical Information
Molecular Formula C35H38Cl2N8O4
CAS Registry Number 84625-61-6
SMILES CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5COC(O5)(CN6C=NC=N6)C 7=C(C=C(C=C7)Cl)Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Chronic obstructive pulmonary disease22.03.01.007--Not Available
Coagulopathy01.01.02.0010.013924%Not Available
Confusional state19.13.01.001; 17.02.03.0050.027847%
Congenital anomaly03.02.01.001--Not Available
Constipation07.02.02.001--
Cough22.02.03.0010.027847%
Cushing's syndrome24.08.04.001; 19.07.03.002; 14.11.01.007; 05.01.01.0010.032488%Not Available
Cushingoid05.01.01.002; 24.08.02.004; 19.07.03.001; 14.11.01.0060.009282%
Cystitis20.03.02.002; 11.01.14.001--
Cystitis haemorrhagic20.03.02.0030.009282%Not Available
Deafness04.02.01.001--Not Available
Death08.04.01.001--
Dehydration14.05.05.001--
Delirium19.13.02.0010.009282%
Depression19.15.01.001--
Dermatitis23.03.04.0020.013924%Not Available
Dermatitis bullous23.03.01.0020.018565%
Dermatitis exfoliative23.03.07.001; 10.01.01.004--
Developmental delay08.01.03.037--Not Available
Diarrhoea07.02.01.001--
Diplopia17.17.01.005; 06.02.06.002--Not Available
Discomfort08.01.08.0030.009282%Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Drug eruption23.03.05.001; 10.01.01.005; 08.01.06.0150.023206%Not Available
Drug hypersensitivity10.01.01.001--Not Available
Drug interaction08.06.03.001--Not Available
Dysgeusia17.02.07.003; 07.14.03.0010.013924%
Dyskinesia17.01.02.0060.009282%
Dyspepsia07.01.02.0010.009282%
Dysphagia07.01.06.003--
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 12 Pages